Urigen   Report issue

For profit Phase 2
Founded: Wilmington DE United States (1997)
Status: Left NME R&D (2021)

Organization Overview

First Clinical Trial
2006
NCT00256542
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2015

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Phase 2 Trials (5)

Key: Urigen (3) Acquired (2)

citric acid (1 trial)

heparin (liquaemin) (2 trials)

lidocaine (xylocaine) (2 trials)

vepoloxamer (1 trial)

vlts-589 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cystitis (Phase 2)

Cystitis, Interstitial (Phase 2)

Pain (Phase 2)

Pelvic Pain (Phase 2)

Somatoform Disorders (Phase 2)

Syndrome (Phase 2)

Urinary Bladder Diseases (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 5
  • # of Trial APIs: 5